On August 31, Wal-Mart announced that people with diabetes will have a new, low-cost option for insulin.
In partnership with Novo Nordisk, Wal-Mart has introduced Novolin human insulin to Wal-Mart’s ReliOn brand of diabetes healthcare products. Available for $16.94 per vial, Novolin is the latest addition to Wal-Mart’s growing ReliOn brand of healthcare products, which include ReliOn insulin syringes, glucose tablets, blood pressure monitors and lancets.
“We believe that this alliance will help the millions of Americans who are managing their diabetes to have easier, affordable access to this life-saving drug,” said Martin Soeters, president of Novo Nordisk Pharmaceuticals, Inc.
Under the ReliOn brand, Novolin will be offered in three human insulin formulations: Novolin R (Regular), Novolin N (NPH) and Novolin 70/30 (70 percent NPH, 30 percent Regular).
Wal-Mart advises consumers to consult with their physician before making any changes in insulin therapy.
Novolin is available in all of Wal-Mart’s 2,600 stores as well as 466 SAM’S Club pharmacies.
For further information, visit Novo Nordisk on the World Wide Web at novo-nordisk.com.